FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Prinston Pharmaceutical Solco Healthcare US Valsartan and Recall

Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 160 MG/12

Prinston Pharmaceutical Inc · Cranbury, NJ

Risk level
Class II
Reported by FDA
Aug 1, 2018
Recall ID
D-0973-2018
Check your lot numberHow we source this data

Summary

Prinston Pharmaceutical recalled Solco Healthcare US Valsartan and starting Jul 13, 2018. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0973-2018 on Aug 1, 2018. Reason: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. Status: Ongoing.

Why it was recalled

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Product description

Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 160 MG/12.5 MG Tablets, 90-count bottles, Rx Only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed by: Solco Healthcare US, LLC Cranbury, NJ 08512 USA NDC 43547-312-09

Lot numbers, UPCs & expiration codes

All lots within expiry.

Where it was sold

United States

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0973-2018
Classification
Class II
Status
Ongoing
Recall initiated
Jul 13, 2018
FDA report date
Aug 1, 2018
Quantity
N/A
Recall type
Voluntary: Firm initiated
Recalling firm
Prinston Pharmaceutical Inc

Original FDA data

Every field from FDA enforcement report D-0973-2018, exactly as published.

Show all FDA fields
City
Cranbury
State
NJ
Status
Ongoing
Country
United States
Event ID
80525
Address
2002 Eastpark Blvd
Code information
All lots within expiry.
Postal code
08512-3514
Report date
Aug 1, 2018
Product type
Drugs
Recall number
D-0973-2018
Classification
Class II
Recalling firm
Prinston Pharmaceutical Inc
Reason for recall
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 160 MG/12.5 MG Tablets, 90-count bottles, Rx Only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed by: Solco Healthcare US, LLC Cranbury, NJ 08512 USA NDC 43547-312-09
Distribution pattern
United States
Recall initiation date
Jul 13, 2018
Initial firm notification
Letter
Center classification date
Jul 20, 2018

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0973-2018, published Aug 1, 2018. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls